
Zealand Pharma will have to wait for results from a phase III study involving a new combination product that the Danish company had high hopes for. Technical issues with the specially developed Fix-Flex-pen have delayed the clinical studies, Zealand Pharma announced Thursday morning.
The combination product, which was heading into the final clinical trial phases, consists of Zealand Pharma’s diabetes drug Lyxumia and the world’s best-selling insulin product, Lantus, from Zealand’s French partner Sanofi.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app